Epigenomics AG
Epigenomics AG: CMS accepts Epigenomics’ application for NCD review
Epigenomics AG / Key word(s): Miscellaneous CMS accepts Epigenomics’ application for NCD review
While CMS has accepted the application, due to the limitation of resources, CMS will not “Open” the NCD review process immediately. Once CMS resources are available the NCD will be “Opened” by initiating a 30-day public comment period and CMS will issue a proposed decision within six months per legal statute. If this proposed coverage decision is positive, another 30-day comment period follows. CMS will publish its final decision within 90 days of the initial proposed decision.
Investor Relations
Forward-Looking Statements This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
03-May-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Epigenomics AG |
Geneststraße 5 | |
10829 Berlin | |
Germany | |
Phone: | +49 30 24345-0 |
Fax: | +49 30 24345-555 |
E-mail: | ir@epigenomics.com |
Internet: | www.epigenomics.com |
ISIN: | DE000A11QW50 |
WKN: | A11QW5 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 806789 |
End of Announcement | DGAP News Service |